Predictive value of IL-6 combined with NLR on the prognosis of patients with triple negative breast cancer after sugery
LIU Junling1 ZHOU Ge2 GUO Hongbin2
1.Department of Surgery Outpatient, Liaoyang City Central Hospital, Liaoning Province, Liaoyang 111000, China;
2.Department of General Surgery, Liaoyang City Central Hospital, Liaoning Province, Liaoyang 111000, China
Abstract：Objective To investigate the predictive value of interleukin-6（IL-6） combined with neutrophil/lymphocyte ratio (NLR) on the prognosis of patients with triple negative breast cancer after surgery. Methods A total of 540 patients with triple negative breast cancer who underwent radical mastectomy in Liaoyang City Central Hospital of Liaoning Province from January 2015 to December 2017 were selected as subjects. Serum IL-6 level of the patients was detected by enzyme-linked immunosorbent assay, and the number of neutrophils and lymphocytes were detected by hematology analyzer, and the NLR value was calculated. Logistic regression was used to analyze the risk factors of poor prognosis of triple negative breast cancer. Receiver operating curve (ROC) was used to evaluate the predictive value of serum IL-6 and NLR to the prognosis of patients. The prognosis of the patients was followed up after discharge. Results By the end of follow-up, 141 patients had poor prognosis, the incidence was 26.11%. The poor prognosis of triple negative breast cancer was correlated with TNM stage, NLR and IL-6 levels (P ＜ 0.05). Logistic regression analysis showed that NLR (OR = 3.652, 95%CI：1.804-7.918, P = 0.000) and IL-6 levels (OR = 2.361, 95%CI：2.169-2.770, P = 0.006) were risk factors for poor prognosis of triple negative breast cancer (P ＜ 0.05). ROC curve showed that the cutoff value of IL-6 was 128.06 ng/mL, the sensitivity was 71.67% and the specificity was 70.83%, the cutoff value of NLR was 2.61, the sensitivity was 75.31% and the specificity was 79.65%. Conclusion Increased levels of NLR and serum IL-6 are risk factors for poor prognosis in triple negative breast cancer. Combined testing for NLR and serum IL-6 can improve sensitivity and specificity and predict poor prognosis in patients.
刘军玲1 周革2 郭宏斌2. IL-6联合NLR对三阴性乳腺癌术后患者预后的预测价值[J]. 中国医药导报, 2020, 17(8): 113-116.
LIU Junling1 ZHOU Ge2 GUO Hongbin2. Predictive value of IL-6 combined with NLR on the prognosis of patients with triple negative breast cancer after sugery. 中国医药导报, 2020, 17(8): 113-116.
[1] Waks AG，Winer EP. Breast Cancer Treatment：A Review [J]. JAMA，2019，321（3）：288-300.
[2] 谭晶波，宋艳利，张宏伟.136例转移性三阴性乳腺癌患者的临床病理特征与预后分析[J].中国综合临床，2017， 33（7）：648-651.
[3] Lee KH，Kim EY，Yun JS，et al. The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer [J]. BMC Cancer，2018，18（1）：938.
[4] Flint TR，Janowitz T，Connell CM，et al. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity [J]. Cell Metab，2016，24（5）：672-684.
[5] 周宁，戴旖旎，白旭光，等.姜黄素对肝癌细胞凋亡及TNF-ɑ、IL-1β、IL-6炎性因子影响的机制研究[J].癌症进展，2017，15（11）：1282-1285.
[6] 顾万娟，杜希林.IL-6、TSGF联合肿瘤标记物CEA、CA724检测在胃癌中的诊断价值[J].检验医学与临床，2019，16（12）：1709-1711.
[7] Liao LJ，Hsu WL，Wang CT，et al. Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio （NLR）in nasopharyngeal carcinoma：A retrospective study of 180 Taiwanese patients [J]. Clin Otolaryngol，2018，43（2）：463-469.
[8] Yodying H，Matsuda A，Miyashita M，et al. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer：A Systematic Review and Meta-analysis [J]. Ann Surg Oncol，2016，23（2）：646-654.
[9] 李杰宝，喻晓程，田野.乳腺癌分子分型与临床病理参数的关系及预后[J].中华实验外科杂志，2018，35（6）：1027-1029.
[10] 苗惠，陈健.HOTAIR在乳腺癌中的研究进展[J].中国医药导报，2019，16（22）：54-57.
[11] 彭晓燕.转移性三阴性乳腺癌的治疗进展[J].中国医药科学，2019，9（16）：56-58.
[12] Li X，Yang J，Peng L，et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer [J]. Breast Cancer Res Treat，2017，161（2）：279-287.
[13] 张劲.适龄妇女乳腺癌和宫颈癌筛查的结果及临床意义[J].当代医学，2018，24（30）：146-147.
[14] 刘宇，姜桐桐，史铁英，等.乳腺癌患者心理弹性影响因素及其干预方法的研究进展[J].中国医药导报，2019， 16（25）：49-52.
[15] Lasry A，Zinger A，Ben-Neriah Y. Inflammatory networks underlying colorectal cancer [J]. Nat Immunol，2016，17（3）：230-240.
[16] Conway EM，Pikor LA，Kung SH，et al. Macrophages，Inflammation，and Lung Cancer [J]. Am J Respir Crit Care Med，2015，193（2）：116-130.
[17] 陈婷，罗序亮，陈雨劼，等.乳腺癌干细胞在肿瘤复发与转移中的作用机制研究进展[J].山东医药，2018，58（42）：99-102.
[18] 罗智萍，刘碧珊，谭宁华.乳腺癌干细胞近年的主要研究进展[J].中国组织工程研究，2017，21（21）：3414-3419.
[19] Wang TY，Yu CC，Hsieh PL，et al. GMI ablates cancer stemness and cisplatin resistance in oral carcinomas stem cells through IL-6/Stat3 signaling inhibition [J]. Oncotarget，2017，8（41）：70422-70430.
[20] Liu L，Li E，Luo L，et al. PSCA regulates IL-6 expression through p38/NF-κB signaling in prostate cancer [J]. Prostate，2017，77（14）：1389-1400.
[21] Ishiguro T，Ohata H，Sato A，et al. Tumor-derived spheroids：Relevance to cancer stem cells and clinical applications [J]. Cancer Sci，2017，108（3）：283-289.
[22] Mochizuki T，Kawahara T，Takamoto D，et al. The neutrophil-to-lymphocyte ratio（NLR）predicts adrenocortical carcinoma and is correlated with the prognosis [J]. BMC Urol，2017，17（1）：49.
[23] Tao L，Zhang L，Peng Y，et al. Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma：A new hypothesis and a new predictor for distant metastasis [J]. Medicine，2016，95（39）：4932.
[24] Lin M，Liang SZ，Shi J，et al. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer [J]. Immunol Lett，2017，191（9）：10-15.
[25] Bidard FC，Proudhon C，Pierga JY. Circulating tumor cells in breast cancer [J]. Mol Oncol，2016，10（3）：418-430.
2020, Vol. 17 
京公网安备 11010502046598号